Trial record 2 of 11 for:    "Pulmonic stenosis"

Pulmonary Arteriopathy-Diagnostics and Therapy

This study has been completed.
Sponsor:
Collaborator:
German Federal Ministry of Education and Research
Information provided by:
Competence Network for Congenital Heart Defects
ClinicalTrials.gov Identifier:
NCT00266175
First received: December 15, 2005
Last updated: October 14, 2008
Last verified: October 2008
  Purpose

Postoperative stenoses of the pulmonary artery vascular system seldom occur alone; they are frequently found in connection with congenital heart defects or malformation syndromes. The resulting increase of afterload represents a serious pressure load for the right ventricle. Depending on the number and severity of the stenoses, gradual functional right ventricular failure is to be expected. Due to limited clinical experience, there has not yet been a consensus concerning the indications for the different therapeutic strategies (balloon dilatation, stent implantation, surgical dilatation techniques). Up to now, only few investigators in few centres use stents as therapy. Therefore, systematic multicenter investigations assessing larger groups of patients undergoing this procedure are not yet available. The same applies to other novel dilatation techniques, such as the use of the "cutting balloon" as therapy for rigid valve stenoses.

By comparing and analysing different invasive forms of treatment (balloon dilatation, stent implantation and surgery), we expect to achieve an optimisation of therapy.

In the study, the outcomes of different strategies as practiced now in German cardiological centers will be compared and the main factors influencing the results will be determined. On the basis of a standardized investigation before and one year after the intervention, these comparisons with respect to the reduction of stenosis and corresponding changes of right ventricular functional and anatomical changes are carried out correcting for known confounders. The assessment of the different included invasive and non-invasive diagnostical procedures with respect to their ability to detect pathological findings and their changes as result of the treatment is an important secondary target of the study.


Condition
Pulmonary Stenosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Pulmonary Arteriopathy; Evaluation of Invasive Treatments of Peripheral Pulmonary Stenosis in Terms of Right Ventricular Function and Patient Exercise Tolerance

Resource links provided by NLM:


Further study details as provided by Competence Network for Congenital Heart Defects:

Primary Outcome Measures:
  • Primary outcome measure:
  • To assess the efficacy of the administered therapy, both the ectasia of the stenosed vessels in
  • relation to the target diameter and the reduction of the pressure gradient in the stenosed vessel
  • are indicated in percent. An evaluation of the therapeutic success takes place after twelve months.
  • Definition of the primary target of therapy:
  • Morphometric:
  • • Expansion of the peripheral pulmonary artery stenosis to at least 80% of the vascular
  • lumen.
  • Manometric:
  • • Gradient reduction over the stenosis of at least 50%.
  • • Reduction in right ventricular systolic pressure, indicated by a reduced ratio of systolic
  • pressure of LV to RV. In this context, there is no definition in terms of a primary target,
  • as right ventricular pressure reduction depends on a variety of parameters (such as
  • number of stenoses of the entire peripheral pulmonary vasculature, potential
  • additional volume load and right ventricular overall function).

Secondary Outcome Measures:
  • Secondary outcome measures:
  • The improvement of the right ventricular systolic and diastolic function as well as reduction of
  • ventricle size and of tricuspid valve incompetence are quantified by means of echocardiography,
  • angiography and, where required, nuclear magnetic resonance tomography.
  • An improvement in capability/quality of life is assessed by means of bicycle ergometer
  • examinations as well as the SF-36 (New England Hospital Inc.) and KINDL questionnaires
  • (Ravens-Sieberer & Bullinger) for adults and children respectively.
  • In assessing the organ-related outcome measures, the different diagnostic imaging methods are
  • compared with each other.

Enrollment: 53
Study Start Date: May 2005
Study Completion Date: July 2008
Detailed Description:

For patients with untreated peripheral pulmonary stenoses, the course of disease is characterised by a chronic pressure load of the right ventricle. In the medium to long term this can lead to right heart failure and cardiac arrhythmia unresponsive to therapy. The probability of these events as well as the time of their occurrence depends on the severity of the stenoses, the duration of stress and a possible additional volume load. Within the scope of the prospective study introduced here, we intend to characterise the stenoses with respect to degree and type and to document the treatment success in terms of decrease of afterload of the right ventricle. In this context, imaging and catheter-based methods as well as respective functional analyses are to be used to provide evidence of a reduction or neutralisation of the pulmonary artery stenoses.

Accordingly, the following questions, or corresponding objectives, can be identified as the base for the conduct of this clinical trial:

  • Morphological and functional categorisation of the angiostenoses and standardisation of the diagnostic procedures. For this purpose, the quantitative criteria for both the morphological degree of stenosis (lumen constriction) and the functional degree of stenosis (pressure gradient) are established by means of cardiac catheterisation and angiography. Non-invasive imaging methods, which have as yet been restricted primarily to echocardiography, are complemented by the method of spin angiography. Compared to conventional angiography, this has the advantage of being less invasive and not involving radiation exposure.
  • On the strength of past experience, the implantation of stents can be viewed as a very promising approach to a treatment with lasting effectiveness of pulmonary artery stenoses. The stents have the advantage of high radial forces that can be offset against the elastic recoil of the vessels occurring after sole dilatation. Furthermore, constrictions that are caused by either kinking of vessels or their compression by neighbouring structures can be dilated sufficiently by the use of stents.
  • With respect to the interconnectedness of all the projects of the Competence Network for Congenital Heart Defects, one essential aspect is the standardisation of diagnostic methods of evaluating right ventricular function. The data obtained during the study are to provide the basis for the development of diagnostic guidelines.
  • Concerning evaluation, particular attention is paid to the patients' self-assessment with respect to their exercise tolerance. In this context, it is a matter of interest to what degree the patients' subjective maximum stress and therefore their quality of life correlate with the objective measurement parameters. The anticipated results are of direct clinical significance for the patients, as they aim at medium to long-term relief of the right ventricle, which may effect a decrease in morbidity and therefore an improvement of the quality of life. This is of particular importance with regard to the fact that there will be a continuously increasing number of patients with congenital heart defects reaching adulthood.
  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with native or postoperative peripheral pulmonary stenoses (PPS; any stenoses that are located distally to the RVOT). Definition of PPS: 40% lumen constriction, or 30% constriction if volume stress is also present. Informed consent of the patient or his/her legal representative is given after instruction. -

Exclusion Criteria:

Patients unable to undergo MRI or spiroergometry for physical or psychological reasons.

Pregnant or nursing patients. Patients affected by other clinically relevant diseases (malignant tumours, infectious diseases, metabolic disorders etc.). Patients with known intolerance of contrast media. Patients with syndromal diseases such as Alagille's syndrome, rubella embryopathy or elfin face syndrome. -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00266175

Locations
Germany
Medizinische Hochschule Hannover
Hannover, Lower Saxony, Germany, D-30625
Herz-und Diabeteszentrum NRW
Bad Oeynhausen, North Rhine-Westphalia, Germany, D-32545
Deutsches Kinderherzzentrum
Sankt Augustin, North Rhine-Westphalia, Germany, D-53757
Universitätsklinikum des Saarlandes
Homburg, Saarland, Germany, D-66421
Deutsches Herzzentrum Berlin
Berlin, Germany, D-13353
Sponsors and Collaborators
Competence Network for Congenital Heart Defects
German Federal Ministry of Education and Research
Investigators
Principal Investigator: Martin Schneider, MD Deutsches Kinderherzzentrum
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00266175     History of Changes
Other Study ID Numbers: MP 1, 01G10210
Study First Received: December 15, 2005
Last Updated: October 14, 2008
Health Authority: Germany: Ethics Commission

Keywords provided by Competence Network for Congenital Heart Defects:
Pulmonary heart disease
Pulmonary hypertension
Stent implantation
Balloon dilatation
Surgery

Additional relevant MeSH terms:
Constriction, Pathologic
Pulmonary Valve Stenosis
Pathological Conditions, Anatomical
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction

ClinicalTrials.gov processed this record on July 23, 2014